

ARG1 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP8976b**Specification****ARG1 Antibody (C-term) Blocking Peptide -
Product Information**Primary Accession [P05089](#)**ARG1 Antibody (C-term) Blocking Peptide -
Additional Information****Gene ID** 383**Other Names**Arginase-1, Liver-type arginase, Type I
arginase, ARG1**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8976b](/products/AP8976b) was selected from the C-term region of human ARG1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**ARG1 Antibody (C-term) Blocking Peptide -
Protein Information****Name** ARG1**Function****ARG1 Antibody (C-term) Blocking Peptide
- Background**

Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by this gene, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia.

**ARG1 Antibody (C-term) Blocking Peptide
- References**

Haraguchi,Y., et.al., J. Clin. Invest. 86 (1), 347-350 (1990)

Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys.

Cellular Location

Cytoplasm. Cytoplasmic granule.

Note=Localized in azurophil granules of neutrophils (PubMed:15546957)

Tissue Location

Within the immune system initially reported to be selectively expressed in granulocytes (polymorphonuclear leukocytes [PMNs]) (PubMed:15546957). Also detected in macrophages mycobacterial granulomas (PubMed:23749634). Expressed in group2 innate lymphoid cells (ILC2s) during lung disease (PubMed:27043409)

**ARG1 Antibody (C-term) Blocking Peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)